Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

In Brief: Genentech's Nutropin AQ

Executive Summary

Genentech's Nutropin AQ: Ready-to-use liquid 10 mg/vial injectable form of somatropin approved Dec. 29 for the same growth hormone insufficiency indications as Nutropin. The recombinant human growth hormone product was available previously in a lyophilized form that required reconstitution with bacteriostatic water. The newly-formulated product has a 28-day shelf-life from initial vial entry compared to 14 days for the lyophilized product. Approval of the Nutropin AQ NDA, submitted in November 1994, was based on results of an open-label clinical trial in previously untreated children with growth hormone insufficiency. Genentech will launch Nutropin AQ in the first quarter at the same price as the lyophilized product...
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS027452

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel